Cougar predation key to ecosystem health
The general disappearance of
cougars from a portion of Zion National Park in the past 70 years has allowed deer populations to dramatically increase, leading to severe ecological damage, loss of cottonwood trees, eroding streambanks, and declining biodiversity. This "trophic cascade" of environmental degradation, all linked to the decline of a major predator, has been shown in a new study...
Cougar at Biology Products
Cougar at Biology Technology
Cougar at Medicine News
Cougar at Medicine Products
Cougar
Description:
Cougar is an Anterior Spinal Implant system. Material that has a modulus of elasticity approximating that of cortical bone. The result is an implant that meets the structural requirements of anterior column support, while optimizing the fusion environment through an open, load sharing design. Incorporates an anatomic design with 5 and 10 degrees of lordosis. Minimal instruments are necessary to i...
Company:Depuy Spine
Cougar Small Footprint
Description:
Cougar is an Anterior Spinal Implant system. Material that has a modulus of elasticity approximating that of cortical bone. The result is an implant that meets the structural requirements of anterior column support, while optimizing the fusion environment through an open, load sharing design. Incorporates an anatomic design with 5 and 10 degrees of lordosis. Minimal instruments are necessary to i...
Company:DePuy Orthopaedics, Inc.
Cougar Large Footprint
Description:
Cougar is an Anterior Spinal Implant system. Material that has a modulus of elasticity approximating that of cortical bone. The result is an implant that meets the structural requirements of anterior column support, while optimizing the fusion environment through an open, load sharing design. Incorporates an anatomic design with 5 and 10 degrees of lordosis. Minimal instruments are necessary to i...
Company:DePuy Orthopaedics, Inc.
Cougar Medium Footprint
Description:
Cougar is an Anterior Spinal Implant system. Material that has a modulus of elasticity approximating that of cortical bone. The result is an implant that meets the structural requirements of anterior column support, while optimizing the fusion environment through an open, load sharing design. Incorporates an anatomic design with 5 and 10 degrees of lordosis. Minimal instruments are necessary to i...
Company:DePuy Orthopaedics, Inc.
Cougar at Medicine Technology
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ESMO Conference
LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 -
Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase I and PhaseII data on the Company's prostate cancer drug candidate CB7630(abiraterone acetate) were presented at the European Society forMedical Oncology (ESMO) Conference, which is currently taking placein Lugano, Switzerland. The data were presented in two oral andposter...
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Jun 4, 2007 -
Cougar Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim Phase Iand Phase II data on the Company's prostate cancer drug candidateCB7630 (abiraterone acetate) was presented at the American Societyof Clinical Oncology (ASCO) Annual Meeting, which is currentlytaking place in Chicago, Illinois. The data was presented in twoposter...
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at AUA Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 -
Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase I and PhaseII data on the Company's prostate cancer drug candidate CB7630(abiraterone acetate) was presented at the American UrologicalAssociation (AUA) Annual Meeting, which is currently taking placein Anaheim, California. The data was presented by Dr. Timothy A.Yap from...
Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR
Annual Meeting Late-Breaking Clinical Trials Session
LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 -
Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase I and PhaseII data on the Company's prostate cancer drug candidate CB7630(abiraterone acetate) was presented at the American Association forCancer Research (AACR) Annual Meeting in Los Angeles, California.The data was presented in two oral presentations as part of aspecial...